logo

For the Inventor, By the Inventor

CA

Tranzyme Pharma Inc.

Calculating rank
USPTO Granted Patents = 19

% Expired Patents = 63.2



Forward Citations = 239

Loading Chart...
Loading Chart...

21 inventors (with patents filed for the assignee):

goldMedal Hamid R Hoveyda (15 out of 51 patents)

silverMedal Mark L Peterson (14 out of 21 patents)

bronzeMedal Graeme Lovat Fraser (11 out of 38 patents)

4.  Luc Ouellet (10 out of 13 patents)

5.  Sylvie Beaubien (7 out of 9 patents)

6.  Yves Dory (7 out of 10 patents)

7.  Pierre Deslongchamps (7 out of 9 patents)

8.  Mahesh Ramaseshan (6 out of 11 patents)

9.  Éric Marsault (6 out of 10 patents)

10.  Ruoxi Lan (5 out of 38 patents)

11.  Kamel Benakli (5 out of 11 patents)

12.  Gérald Villeneuve (4 out of 4 patents)

13.  Daniel Fortin (4 out of 4 patents)

14.  Eric Marsault (3 out of 24 patents)

15.  Carl St-Louis (3 out of 8 patents)


19 patents:

1. 8557765 - Spatially-defined macrocycles incorporating peptide bond surrogates (2013-10-15),
2. 8497242 - Processes for intermediates for macrocyclic compounds (2013-07-30),
3. 8450268 - Methods of using macrocyclic modulators of the ghrelin receptor (2013-05-28),
4. 8440851 - Spatially-defined macrocyclic compounds useful for drug discovery (2013-05-14),
5. 8349887 - Methods of treating cachexia with macrocyclic modulators of the ghrelin receptor (2013-01-08),
6. 8334256 - Pharmaceutical salts of macrocyclic modulators of the ghrelin receptor (2012-12-18),
7. 8188216 - Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery (2012-05-29),
8. 8129561 - Processes for intermediates for macrocyclic compounds (2012-03-06),
9. 8088733 - Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders (2012-01-03),
10. 8022252 - Spatially-defined macrocyclic compounds useful for drug discovery (2011-09-20),
11. 8008440 - Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery (2011-08-30),
12. RE42624 - Methods of using macrocyclic modulators of the ghrelin receptor (2011-08-15),
13. RE42013 - Macrocyclic modulators of the ghrelin receptor (2010-12-27),
14. 7550431 - Spatially-defined macrocycles incorporating peptide bond surrogates (2009-06-23),
15. 7521420 - Macrocyclic antagonists of the motilin receptor (2009-04-21),
Company Overview
Tranzyme Pharma Inc. is a biopharmaceutical company based in California, specializing in the development of innovative therapeutics for gastrointestinal and metabolic diseases. The organization focuses on leveraging its proprietary technology platform to discover and advance novel drug candidates aimed at addressing significant unmet medical needs. Tranzyme's research encompasses a range of therapeutic areas, emphasizing the importance of enhancing patient outcomes through targeted treatment solutions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

19 Patents

#26 in

#778 in Canada

#32,705 in the World

CA
CA

Tranzyme Pharma Inc.

Forward Citations = 239

21 inventors:

goldMedal Hamid R Hoveyda (15 out of 51 patents)

silverMedal Mark L Peterson (14 out of 21 patents)

bronzeMedal Graeme Lovat Fraser (11 out of 38 patents)

4.  Luc Ouellet (10 out of 13 patents)

5.  Sylvie Beaubien (7 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Tranzyme Pharma Inc.. Retrieved from https://idiyas.com/company/tranzyme-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…